Clinical trials are the engine of medical progress — every treatment available today, from antibiotics to immunotherapies, reached patients through the clinical research pathway. For stem cell therapy in particular, clinical trials are especially important because many applications remain investigational and the evidence base is still maturing. This guide explains what clinical trial participation involves, how to find legitimate studies, what questions to ask, and how to make an informed decision about whether enrollment is right for you. [1]

Why clinical trials matter for stem cell therapy. Mesenchymal stem cell (MSC) therapy has shown promise across a wide range of conditions — from orthopedic injuries to autoimmune diseases to neurodegenerative disorders — but for most indications, the highest-quality evidence comes from clinical trials, not routine clinical practice. Trials generate the safety and efficacy data that regulatory agencies require for approval, and they provide participants with access to protocols that have been reviewed by ethics committees and scientific experts. [2]

Trial participation is not the same as paying for treatment. Many patients confuse clinical trials with medical tourism — traveling to a clinic and paying for an unproven therapy. Legitimate clinical trials are fundamentally different: they follow a structured protocol approved by an institutional review board (IRB) or ethics committee, they typically do not charge participants for the investigational product, they include systematic safety monitoring and follow-up, and their results — whether positive or negative — are intended for publication. Understanding this distinction is the first step in protecting yourself. [3]

This guide covers what you need to know. We walk through clinical trial phases and types, the current landscape of MSC clinical research, how to search for and evaluate trials, eligibility criteria and the screening process, informed consent and your rights as a participant, the risks and benefits of enrollment, what to expect logistically, and specific considerations for international participants considering trials in Thailand and the Asia-Pacific region.

What Is a Clinical Trial?

A clinical trial is a research study in which human volunteers receive an investigational intervention — a drug, biologic, device, or procedure — according to a predefined protocol, with the goal of evaluating its safety and effectiveness. Clinical trials are the bridge between laboratory discovery and approved medical treatment.

The four phases of clinical research. Phase I trials test safety in a small group (20–80 participants), determining safe dosage ranges and identifying side effects. Phase II trials expand to several hundred participants and begin to assess efficacy — does the intervention produce the intended biological effect? Phase III trials involve hundreds to thousands of participants, comparing the new intervention against the current standard of care or placebo in a randomized, often double-blinded design. Phase IV trials occur after regulatory approval, monitoring long-term safety and effectiveness in the general population. [4] Most MSC trials currently in progress are Phase I/II or Phase II — the field is still relatively young.

Randomized controlled trials are the gold standard. In an RCT, participants are randomly assigned to either the treatment group or a control group (which may receive placebo or standard care). Randomization eliminates selection bias, and blinding — where neither participant nor investigator knows who is receiving the active treatment — eliminates expectation bias. When you read about "double-blind, randomized, placebo-controlled" trials, you are reading about the highest standard of clinical evidence. [5]

Clinical Trial Phases at a Glance

Phase I: Safety and dosing (20–80 people) · Phase II: Efficacy and side effects (100–300) · Phase III: Comparison to standard care (300–3,000+) · Phase IV: Post-approval long-term monitoring. The majority of MSC trials today are Phase I/II.

The MSC Clinical Trial Landscape

As of 2026, over 1,500 clinical trials involving mesenchymal stem cells have been registered on ClinicalTrials.gov and other international registries. These span conditions from osteoarthritis to graft-versus-host disease to multiple sclerosis — and the number continues to grow at approximately 15–20 percent annually. [6]

Where the evidence is strongest. Conditions with the most mature MSC clinical trial data include osteoarthritis of the knee, where multiple randomized trials have demonstrated significant cartilage preservation and pain reduction; graft-versus-host disease (GvHD), where MSC therapy is already approved in several countries including Japan and Canada; fistulizing Crohn's disease, with Phase III data supporting regulatory approvals in Europe; critical limb ischemia, spinal cord injury, and acute respiratory distress syndrome (ARDS), where Phase I/II data has been encouraging. [7] [8]

Where evidence is still emerging. For conditions such as autism spectrum disorder, Alzheimer's disease, Parkinson's disease, COPD, and many autoimmune conditions, the clinical trial evidence is more limited — typically small Phase I/II studies with signals of potential benefit but not yet definitive results. Patients considering trials in these areas should understand that they are participating in early-stage research, not receiving a proven treatment.

The importance of trial registration. Legitimate clinical trials are registered on public databases before they begin recruiting. Registration is an ethical obligation — it prevents selective reporting of positive results, allows patients and physicians to find ongoing studies, and creates accountability. The major registries include ClinicalTrials.gov (United States), the EU Clinical Trials Register, the WHO International Clinical Trials Registry Platform (ICTRP), the Chinese Clinical Trial Registry, and the Japan Registry of Clinical Trials (jRCT). [9]

How to Find Legitimate Clinical Trials

Finding the right trial requires patience and method. There are thousands of registered stem cell trials — but not all are well-designed, actively recruiting, or appropriate for any given patient. A systematic search is the best approach.

Start with public registries. ClinicalTrials.gov is the largest and most accessible — it allows you to search by condition, location, intervention type, and trial phase. The WHO ICTRP portal searches across multiple national registries simultaneously. Both services are free and do not require registration. Key search terms for MSC trials include "mesenchymal stem cell," "mesenchymal stromal cell," "MSC," "umbilical cord stem cell," and "Wharton's Jelly." [10]

Understand the study record. Every entry includes the trial's status (recruiting, active not recruiting, completed, terminated), phase, conditions studied, intervention details, eligibility criteria, locations, and contact information. A "recruiting" status means the trial is actively enrolling; "active, not recruiting" means enrollment is closed but participants are still being followed. Avoid trials with "unknown status" — these are typically abandoned and have not been updated in years.

Verify the sponsor. Legitimate trials are sponsored by academic medical centers, research institutes, government agencies, or reputable biotechnology companies. Be wary of trials whose sole sponsor is a for-profit clinic with no academic or institutional affiliations — these may be marketing exercises disguised as research. Verify the sponsoring institution by searching for it independently. A trial should have a clearly identified principal investigator (PI) with verifiable credentials and publications. [11]

Eligibility: Who Can Participate?

Every clinical trial has inclusion and exclusion criteria — specific characteristics that determine who can and cannot enroll. These criteria serve two purposes: protecting participant safety by excluding those for whom the intervention might be dangerous, and creating a homogeneous study population so that results are interpretable.

Typical inclusion criteria for MSC trials. Confirmed diagnosis of the target condition, a defined age range (often 18–75 for adult trials), adequate organ function (liver, kidney, heart), ability to provide informed consent, and willingness to comply with follow-up visits. Some trials also require that standard treatments have been tried and failed — this is called "treatment-refractory" criteria. [12]

Common exclusion criteria. Active cancer or history of malignancy within the past five years, active infection (particularly HIV, hepatitis B/C, tuberculosis), pregnancy or breastfeeding, severe organ dysfunction, recent surgery or major medical event, current participation in another investigational trial, and use of immunosuppressive medications above a certain threshold. Exclusion criteria exist to protect you — if a trial has minimal exclusions, that is a potential red flag.

The screening process. If you appear to meet eligibility criteria based on your application, you will undergo a screening visit that typically includes a detailed medical history, physical examination, laboratory tests (blood count, chemistry, infectious disease panel, pregnancy test where applicable), imaging as indicated, and a thorough discussion of the trial protocol. Expect this to take several hours. You may be found ineligible at this stage — this is common and not a reflection on your health, only on the trial's specific requirements.

Informed Consent: Your Most Important Protection

Informed consent is the ethical and legal foundation of clinical research. It is not simply a document you sign — it is a process through which you understand, in plain language, exactly what participation involves, before you agree to it. No legitimate trial enrolls participants without documented informed consent. [13]

What the consent form must include. The purpose and duration of the study, a clear description of all procedures (including those that are experimental vs. standard care), the potential risks and benefits, alternative treatments available outside the trial, compensation for injury (in many countries, sponsors are required to provide medical care for research-related injuries), confidentiality protections, the voluntary nature of participation, and the right to withdraw at any time without penalty or loss of medical care.

Questions to ask before signing. Take the consent form home. Discuss it with family, your primary physician, or a patient advocate. Then ask the research team: "What is the evidence that this intervention might work for my condition?" "What are the known risks from previous studies?" "Who is funding the trial, and do the investigators have financial conflicts of interest?" "What happens to my data and biological samples?" "If the treatment works, can I continue receiving it after the trial ends?" A research team that welcomes these questions and answers them clearly demonstrates the transparency that marks a well-run study. [14]

You cannot waive your right to informed consent, and you cannot be enrolled in a trial without it. If anyone asks you to sign a consent form without explaining its contents, or pressures you to sign immediately, you are not participating in ethical research — you are being exploited.

— Declaration of Helsinki, World Medical Association

Risks and Benefits: A Realistic Assessment

Trial participation carries both potential benefits and genuine risks — and understanding both is essential to making an informed decision.

Potential benefits. Access to an investigational therapy that is not yet available to the general public — for conditions where standard treatments have limited effectiveness, this can be significant. Close monitoring by a research team, often at no cost for the investigational aspects of care. Contribution to medical knowledge that may help future patients — every approved treatment exists because past participants volunteered for trials. In some trials, all participants eventually receive the active treatment — those randomized to the control group may be offered the intervention after the primary study period ends (a "crossover" design). [15]

Potential risks. The investigational treatment may not work — and in a placebo-controlled trial, you may not receive the active treatment at all. Side effects may occur that were not anticipated from earlier studies. MSC therapy carries specific risks including infusion reactions (fever, chills, headache — typically transient), infection at the administration site (particularly for intra-articular or intrathecal injections), immune reactions (though allogeneic MSCs are generally considered low-immunogenicity), and — rarely — ectopic tissue formation or thromboembolic events. [16] The trial protocol should clearly explain the known and potential risks, and the research team should be prepared to manage adverse events.

The uncertainty factor. The fundamental nature of a clinical trial is that the outcome is unknown — that is why the research is being done. No investigator can guarantee benefit, and the informed consent process should make this clear. If anyone promises or guarantees a positive outcome, you are not in a clinical trial — you are being sold an unproven treatment.

What to Expect: The Trial Journey

Participating in a clinical trial is a commitment — it requires time, travel, and adherence to a protocol. Understanding the practical logistics before you enroll helps set realistic expectations.

Screening

1–2 visits. Medical history, physical exam, labs, imaging. Review and sign informed consent. Confirmation of eligibility.

Treatment

1–3 visits. Baseline assessments, administration of the investigational product (single dose or series), immediate post-treatment monitoring.

Follow-Up

6–24 months. Regular assessments at defined intervals — physical exams, questionnaires, labs, imaging. Tracking outcomes and adverse events.

Time commitment. Most MSC trials require follow-up of at least 6 months, and many extend to 12 or 24 months. Expect 5–10 study visits over the course of the trial, with more frequent visits in the early months. Some trials provide transportation assistance or reimbursement for travel expenses, particularly for participants traveling long distances — ask about this during screening.

Costs: what is covered. In legitimate clinical trials, the investigational product and all study-related procedures are typically provided at no cost to the participant. However, "standard of care" procedures that would be performed regardless of the trial may still be billed to you or your insurance. The consent form should clearly delineate which costs are covered by the sponsor and which are your responsibility. Never join a trial that asks you to pay for the investigational treatment itself — this is a hallmark of "pay-to-participate" schemes that exploit patients rather than conduct valid research. [3]

International Participants and Trials in Thailand

Thailand has become a significant hub for MSC clinical research, with several academic medical centers and regulatory-compliant facilities conducting registered trials. For international patients, participating in a Thai-based trial offers access to protocols at a fraction of the cost of Western academic centers — but it requires careful navigation. [17]

The regulatory environment. Clinical trials in Thailand are regulated by the Thai Food and Drug Administration (Thai FDA) and must receive approval from an accredited institutional review board or ethics committee. Thailand adheres to ICH Good Clinical Practice (GCP) guidelines, which are the international standard for clinical trial conduct. Trials must be registered on the Thai Clinical Trials Registry (TCTR), which is a WHO ICTRP primary registry. [18]

Practical considerations for international participants. Language support — ensure the consent form and all study materials are available in a language you fully understand (English is standard in Thai-based international trials). Visa arrangements — clinical trial participation may qualify for a medical visa; confirm with the Thai embassy or consulate in your country. Continuity of care — establish a plan with your home physician for post-trial follow-up. Communication — confirm how the research team will communicate with you and your local doctor during and after the trial. Travel insurance — standard travel insurance may not cover clinical trial participation; inquire about study-provided coverage. [19]

Red Flags: Spotting Unethical "Trials"

The term "clinical trial" is occasionally misused by commercial operators to lend legitimacy to what is essentially an unregulated treatment service. Recognizing the difference can prevent harm.

How to Distinguish a Real Clinical Trial From a Commercial Offering

  1. Registration. A real trial is publicly registered with a unique NCT or equivalent identifier before recruitment begins. Ask for the registration number and verify it on ClinicalTrials.gov or the WHO ICTRP.
  2. No charges for the investigational product. If you are being charged for the stem cells themselves, it is not a clinical trial — it is a commercial treatment service. [3]
  3. IRB/ethics committee approval. Every legitimate trial has received independent ethical review. Ask which committee approved the study and verify independently.
  4. Informed consent. A proper consent process with a formal, multi-page document written in plain language. Not a one-page waiver.
  5. Principal investigator. A named physician-scientist with relevant qualifications, not a sales representative. Search for their name in PubMed — real investigators have research publications.
  6. Follow-up protocol. A structured follow-up schedule with defined outcome measures. Not "call us if you have problems."
  7. Publication intent. Real trials intend to publish results regardless of outcome. Ask: "Where will the results be published, and when?"

Limitations and Realistic Expectations

This guide aims to help patients navigate the clinical trial landscape, but it has important limitations. No guide can substitute for individualized medical advice, and not every trial is appropriate for every patient. Clinical trial participation is a personal decision that should be made in consultation with your treating physician, family, and — ideally — a patient advocate or independent medical advisor who can help you evaluate the specific study.

Furthermore, the outcomes of clinical trials are inherently unpredictable. A trial that looks promising on paper may fail to demonstrate efficacy. Participation carries real risks, and there is no guarantee of personal benefit. The primary purpose of clinical research is to generate generalizable knowledge that benefits future patients — and while many participants do experience benefit, this should not be the expectation driving enrollment. [20]

At VELAR Center, we are committed to evidence-based medicine and support the clinical research enterprise that advances it. We encourage all patients considering stem cell therapy to explore registered clinical trials as one potential pathway to access, and we are available to help you understand the landscape — whether or not your path leads through our doors.

Frequently Asked Questions

What is the difference between a clinical trial and paying for stem cell treatment at a clinic?

A clinical trial is a research study with a predefined protocol, ethical oversight, systematic safety monitoring, and — critically — no charge for the investigational product. Paying for treatment at a clinic is a commercial transaction, often for an unproven therapy, without the protections that trials provide. If you are being asked to pay for stem cells, you are not in a clinical trial.

How do I find MSC clinical trials near me or in Thailand?

Search ClinicalTrials.gov with your condition name plus "mesenchymal stem cell" or "MSC," and filter by location and "recruiting" status. For Thailand-based trials, also search the Thai Clinical Trials Registry (TCTR) at clinicaltrials.in.th. Academic centers in Bangkok, including Chulalongkorn University and Mahidol University, are active in MSC research.

Do I have to pay to participate in a clinical trial?

No — the investigational product and study-related procedures are typically covered by the trial sponsor. You may be responsible for travel, accommodation, and standard-of-care procedures that would be needed regardless of the trial. Any legitimate trial clearly states what costs you are expected to bear. If you are asked to pay for the stem cells themselves, it is not a clinical trial.

Can I leave a clinical trial after I have enrolled?

Yes. Participation is entirely voluntary, and you have the right to withdraw at any time, for any reason, without penalty or loss of medical care to which you are otherwise entitled. Withdrawing does not affect your relationship with the institution or your access to standard medical treatment.

What happens if I am injured during a clinical trial?

Clinical trial sponsors are ethically and — in many jurisdictions, legally — obligated to provide medical care for research-related injuries. The informed consent document should specify the compensation and treatment provisions. Ask for this explicitly before enrolling. In Thailand, trial-related injury coverage is part of GCP-compliant trial conduct.

How do I know if a clinical trial is legitimate?

Verify the trial's NCT or equivalent registration number on a public registry. Confirm that an accredited IRB or ethics committee approved the study. Identify the principal investigator and sponsor institution — both should be searchable independently. If the trial charges for the investigational product, lacks a named PI, or has no public registration, it is not a legitimate clinical trial.

References

  1. Friedman LM, Furberg CD, DeMets DL, Reboussin DM, Granger CB. Fundamentals of Clinical Trials. 5th ed. Springer. 2015. doi:10.1007/978-3-319-18539-2 ↩
  2. Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824-833. doi:10.1016/j.stem.2018.05.004 ↩
  3. Sipp D, Caulfield T, Kaye J, et al. Marketing of unproven stem cell-based interventions: a call to action. Science Translational Medicine. 2017;9(397):eaag0426. doi:10.1126/scitranslmed.aag0426 ↩
  4. Umscheid CA, Margolis DJ, Grossman CE. Key concepts of clinical trials: a narrative review. Postgraduate Medicine. 2011;123(5):194-204. doi:10.3810/pgm.2011.09.2475 ↩
  5. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. doi:10.1136/bmj.c332 ↩
  6. Kabat M, Bobkov I, Kumar S, Grumet M. Trends in mesenchymal stem cell clinical trials 2004–2018: Is efficacy optimal in a narrow dose range? Stem Cells Translational Medicine. 2020;9(1):17-27. doi:10.1002/sctm.19-0202 ↩
  7. Moll G, Ankrum JA, Olson SD, Nolta JA. Improved MSC minimal criteria to maximize patient safety. Stem Cells Translational Medicine. 2022;11(3):246-258. doi:10.1093/stcltm/szab018 ↩
  8. Pittenger MF, Discher DE, Péault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regenerative Medicine. 2019;4:22. doi:10.1038/s41536-019-0083-6 ↩
  9. Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrials.gov results database — update and key issues. New England Journal of Medicine. 2011;364(9):852-860. doi:10.1056/NEJMsa1012065 ↩
  10. De Angelis C, Drazen JM, Frizelle FA, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. New England Journal of Medicine. 2004;351(12):1250-1251. doi:10.1056/NEJMe048225 ↩
  11. Turner L, Knoepfler P. Selling stem cells in the USA: assessing the direct-to-consumer industry. Cell Stem Cell. 2016;19(2):154-157. doi:10.1016/j.stem.2016.06.007 ↩
  12. Bauer G, Elsallab M, Abou-El-Enein M. Concise review: a comprehensive analysis of reported adverse events in patients receiving unproven stem cell-based interventions. Stem Cells Translational Medicine. 2018;7(9):676-685. doi:10.1002/sctm.17-0282 ↩
  13. Grady C. Enduring and emerging challenges of informed consent. New England Journal of Medicine. 2015;372(9):855-862. doi:10.1056/NEJMra1411250 ↩
  14. Nishimura A, Carey J, Erwin PJ, Tilburt JC, Murad MH, McCormick JB. Improving understanding in the research informed consent process: a systematic review of 54 interventions tested in randomized control trials. BMC Medical Ethics. 2013;14:28. doi:10.1186/1472-6939-14-28 ↩
  15. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis. PLoS One. 2012;7(10):e47559. doi:10.1371/journal.pone.0047559 ↩
  16. Squassina A, Meloni A, Chillotti C, Pisanu C. Stem cell therapies in clinical trials: a review of safety and efficacy. Journal of Clinical Medicine. 2023;12(4):1348. doi:10.3390/jcm12041348 ↩
  17. Cohen CB, Cohen PJ. International stem cell tourism and the need for effective regulation. Kennedy Institute of Ethics Journal. 2010;20(1):27-49. doi:10.1353/ken.0.0305 ↩
  18. Vijayananthan A, Nawawi O. The importance of Good Clinical Practice guidelines and its role in clinical trials. Biomedical Imaging and Intervention Journal. 2008;4(1):e5. doi:10.2349/biij.4.1.e5 ↩
  19. Connolly R, O'Brien T, Flaherty G. Stem cell tourism — a web-based analysis of clinical services available to international travellers. Travel Medicine and Infectious Disease. 2014;12(6):695-701. doi:10.1016/j.tmaid.2014.09.008 ↩
  20. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. Cytotherapy. 2006;8(4):315-317. doi:10.1080/14653240600855905 ↩